LivsMed
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
LivsMed develops and manufactures articulating surgical instruments used in minimally invasive (laparoscopic) surgery, procedures performed through small incisions using a camera and slim tools, avoiding the need to open the body fully.
Its instruments are used by surgeons in hospitals and are cleared for use in major markets including the United States, Europe, and Japan. Listed on KOSDAQ, Korea's tech-focused stock exchange, the company's product range centres on its ArtiSential articulating laparoscopic instrument, alongside a vascular stapler, a surgical stapler, a camera system, and a surgical robot, all built around a shared multi-joint end-tool technology.
Summary is AI-generated and may contain errors · figures from DART filings
LivsMed in five facts
What does LivsMed do?
LivsMed develops and manufactures articulating surgical instruments used in minimally invasive (laparoscopic) surgery, procedures performed through small incisions using a camera and slim tools, avoiding the need to open the body fully.
Where is LivsMed listed and in which sector?
LivsMed (Korean name: 리브스메드) trades under KRX code 491000 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Health Care sector, Medical Devices.
How large is LivsMed?
Its market capitalisation was US$799.6M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were LivsMed's latest annual revenue and operating profit?
For fiscal year 2025, LivsMed reported revenue of US$38.6M, an operating loss of US$17.1M and a net loss of US$17.3M, per its annual report on DART (data retrieved from DART on 2026-10-02).
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-10-02
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- Investor relations (IR) meetingOct 1
- Investor relations (IR) meetingOct 1
- Change of 30% or more in revenue or profit/loss structure (15% for large companies)
LivsMed reported consolidated results for FY2025: revenue of US$35.7M (+88.7% year on year), an operating loss of US$15.8M and a net loss of US$16M.
Earnings · Feb 27